Adcetris brentuximab vedotin: Preliminary Phase II data

Preliminary data from 42 evaluable patients with CD30-undetectable relapsed/refractory DLBCL in an open-label, North American Phase II trial showed that 1.8 mg/kg IV Adcetris every 3 weeks

Read the full 277 word article

Trial Subscription

Get a two-week free trial subscription to BioCentury

SIGN UP

Article Purchase

This article may not be distributed to non-subscribers
More Info >PURCHASE